Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG rhG-CSF for primary prevention of chemotherapy-induced neutropenia in ovarian cancer
ChiCTR2500102243Phase 2Not yet recruiting
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- May 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegfilgrastim in ovarian cancer and neutropenia, sponsored by Liaoning Province Cancer Hospital. Primary endpoint: Incidence of grade 3/4 neutropenia. Planned start May 2025; status: not yet recruiting.
02
Drugs
pegfilgrastim
03
Conditions
ovarian cancerneutropenia
Beyond the preview
Go deeper on ChiCTR2500102243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102243.